載入中
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.
前收盤價
US$3.07
+US$0.02 · +0.66%
盤中時間採用ET。市場資料可能有所延遲。
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.
日內區間
目前US$3.07
52週區間
目前US$3.07
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
持有
估值
94
深度低估
情緒
41
多空交錯
風險
69
高風險
動能
18
強勢下行
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.
日內區間
目前US$3.07
52週區間
目前US$3.07
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 752.8萬 USD | 334.4萬 USD | 7.3萬 USD | — | — |
| 毛利 | 752.8萬 USD | 334.4萬 USD | 7.3萬 USD | — | — |
| 研究與開發 | 997.5萬 USD | 1045.7萬 USD | 1191.6萬 USD | 1705.6萬 USD | 1958.3萬 USD |
| 銷售、一般及管理費用 | 648.6萬 USD | 731.7萬 USD | 1007.9萬 USD | 806.4萬 USD | 618萬 USD |
| 營業費用 | 1676.2萬 USD | 1807.6萬 USD | 2227萬 USD | 2526.4萬 USD | 2583.4萬 USD |
| 利息收入 | 29.9萬 USD | 25.4萬 USD | 15.4萬 USD | 283.1萬 USD | 203.9萬 USD |
| 利息支出 | 87.6萬 USD | 96.2萬 USD | 89.7萬 USD | 150.8萬 USD | 91.5萬 USD |
| 折舊和攤銷 | 61.5萬 USD | 60.7萬 USD | 61.5萬 USD | 57.1萬 USD | 34.4萬 USD |
| 營業利益 | −923.4萬 USD | −1473.2萬 USD | −2219.7萬 USD | −2526.4萬 USD | −2583.4萬 USD |
| 淨利 | −770.7萬 USD | −1056.7萬 USD | −2212.5萬 USD | −2316.9萬 USD | −2453.2萬 USD |
公司資料更新於 2026年10月11日。
第三方分析師預期可能變動，並非 GoAI 建議。
評級樣本有限，僅4項
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2025年1月14日 | 1:5 | — | — |
股票分割 | 2024年1月22日 | 1:10 | — | — |
已生效 2025年1月14日
1:5
已生效 2024年1月22日
1:10
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
